Finance

Generic pharmaceutical firm reports loss of $0.09 per share

Published in Drug Week, December 3rd, 2004

Alpharma, Inc., (ALO) announced a diluted loss per share of $0.09 for the third quarter of 2004.

These results include previously announced charges of $0.07 diluted earnings per share (DEPS) related to a legal settlement and certain inventory and fixed asset write-offs, all related to a U.S. generic nasal spray product. The company's guidance for the quarter was approximately break even.

Third quarter 2004 net revenues were $298 million, a decrease of 6% versus 2003. Excluding the impact of foreign currency, revenues declined 9%.

This revenue decline was due primarily to lower U.S. Human Pharmaceuticals revenues, partially offset...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry